Incidence and clinical features of the @entity5126 -associated @entity1162 : implications for XXXX care.

@entity1 @entity1166 @entity713 @entity5126 @entity955 @entity972 @entity1162 @entity943 @entity1371
@entity5126 therapy is one of the most common causes of the acquired @entity1162 and @entity1166 . In reviewing clinical data in 24 @entity1 with the @entity5126 -associated @entity1162 , 20 of whom had @entity1166 , we have delineated several heretofore unreported or underemphasized features. (1) This adverse drug reaction occurred either in @entity1 who were being treated for frequent nonsustained @entity943 or for @entity955 or flutter. (2) In @entity1 being treated for @entity955 , @entity1166 occurred only after conversion to sinus rhythm. (3) Although most @entity1 developed the syndrome within days of starting @entity5126 , four had @entity1166 during long-term @entity5126 therapy, usually in association with @entity1371 . (4) Because of the large experience with this entity at our institution, we have been able to estimate the risk as at least 1.5% per year. (5) Twenty of the 24 @entity1 had at least one major, easily identifiable, associated risk factor including serum @entity972 below 3.5 mEq/L (four); serum @entity972 between 3.5 and 3.9 mEq/L (nine); high-grade @entity713 (four); and marked underlying, (unrecognized) @entity1162 (two). Plasma @entity5126 concentrations were low, being at or below the lower limit of the therapeutic range in half of @entity1 . The ECG features typically included absence of marked QRS widening, marked @entity1162 (by definition), and a stereotypic series of cycle length changes just prior to the onset of @entity1166 . @entity1166 started after the T wave of a markedly prolonged QT interval that followed a cycle that had been markedly prolonged (usually by a post ectopic pause).(ABSTRACT TRUNCATED AT 250 WORDS)
